The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Zenas Biopharma Inc shares valued at $1,200,002 were purchased by Nunn Jason Raleigh on Oct 09 ’25. At $19.00 per share, Nunn Jason Raleigh acquired 63,158 shares. The insider’s holdings grew to 1,173,395 shares worth approximately $42.61 million following the completion of this transaction.
Also, SR ONE CAPITAL MANAGEMENT, LLC purchased 126,315 shares, netting a total of over 2,399,985 in proceeds. Following the buying of shares at $19.00 each, the insider now holds 1,917,895 shares.
Before that, ENRIGHT PATRICK G had added 105,265 shares to its account. In a trade valued at $2,000,035, the Director bought Zenas Biopharma Inc shares for $19.00 each. Upon closing the transaction, the insider’s holdings increased to 105,265 shares, worth approximately $66.54 million.
As published in their initiating research note from Wedbush on March 20, 2025, Zenas Biopharma Inc [ZBIO] has been an Outperform and the price target has been revised to $35. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of December 16, 2024, H.C. Wainwright has initiated its “Buy” rating for ZBIO. Earlier on November 05, 2024, Rodman & Renshaw initiated its rating. Their recommendation was “a Buy” for ZBIO stock.
Analyzing ZBIO Stock Performance
On last trading session, Zenas Biopharma Inc [NASDAQ: ZBIO] plunged -0.74% to $36.31. The stock’s lowest price that day was $34.69, but it reached a high of $36.53 in the same session. During the last five days, there has been a drop of approximately -15.18%. Over the course of the year, Zenas Biopharma Inc shares have jumped approximately 269.00%. Shares of the company reached a 52-week high of $44.60 on 12/24/25 and a 52-week low of $5.83 on 01/28/25.
Support And Resistance Levels for Zenas Biopharma Inc (ZBIO)
According to the 24-hour chart, there is a support level at 35.16, which, if violated, would cause prices to drop to 34.00. In the upper region, resistance lies at 37.00. The next price resistance is at 37.68. RSI (Relative Strength Index) is 47.21 on the 14-day chart, showing neutral technical sentiment.
Is Zenas Biopharma Inc subject to short interest?
Stocks of Zenas Biopharma Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.34 million shares to 4.95 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 4.61 million shares. A jump of 6.93% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 15.8 of the overall float, the days-to-cover ratio (short ratio) jumped to 15.8.
Which companies own the most shares of Zenas Biopharma Inc (ZBIO)?
In terms of Zenas Biopharma Inc share price expectations, FactSet research, analysts set an average price target of 44 in the next 12 months, up nearly 20.28% from the previous closing price of $36.58. Analysts anticipate Zenas Biopharma Inc stock to reach 52 by 2026, with the lowest price target being 34. On October 08, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and initiated coverage with a $40.
